HK1020530A1 - Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators - Google Patents

Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Info

Publication number
HK1020530A1
HK1020530A1 HK99105147A HK99105147A HK1020530A1 HK 1020530 A1 HK1020530 A1 HK 1020530A1 HK 99105147 A HK99105147 A HK 99105147A HK 99105147 A HK99105147 A HK 99105147A HK 1020530 A1 HK1020530 A1 HK 1020530A1
Authority
HK
Hong Kong
Prior art keywords
triazoles
diphenyl
substituted
metal chelators
pharmaceutical metal
Prior art date
Application number
HK99105147A
Other languages
English (en)
Inventor
Rene Lattmann
Pierre Acklin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1020530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1020530A1 publication Critical patent/HK1020530A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK99105147A 1996-06-25 1999-11-09 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators HK1020530A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (1)

Publication Number Publication Date
HK1020530A1 true HK1020530A1 (en) 2000-05-12

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99105147A HK1020530A1 (en) 1996-06-25 1999-11-09 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Country Status (37)

Country Link
US (3) US6465504B1 (es)
EP (1) EP0914118B1 (es)
JP (1) JP3541042B2 (es)
KR (1) KR100616378B1 (es)
CN (1) CN1146415C (es)
AP (1) AP1127A (es)
AR (1) AR007479A1 (es)
AT (1) ATE226435T1 (es)
AU (1) AU718037B2 (es)
BG (1) BG64248B1 (es)
BR (1) BR9709973A (es)
CA (1) CA2255951C (es)
CY (2) CY2429B1 (es)
CZ (1) CZ291470B6 (es)
DE (3) DE122007000020I2 (es)
DK (1) DK0914118T3 (es)
ES (1) ES2187785T3 (es)
FR (1) FR06C0049I2 (es)
GE (1) GEP20084355B (es)
HK (1) HK1020530A1 (es)
HU (1) HU226232B1 (es)
IL (1) IL127212A0 (es)
LT (1) LTC0914118I2 (es)
LU (1) LU91291I2 (es)
MY (1) MY129541A (es)
NL (1) NL300248I2 (es)
NO (3) NO317180B1 (es)
NZ (1) NZ333308A (es)
OA (1) OA10946A (es)
PL (1) PL194758B1 (es)
PT (1) PT914118E (es)
RU (1) RU2208010C2 (es)
SI (1) SI0914118T1 (es)
SK (1) SK284319B6 (es)
TR (1) TR199802693T2 (es)
TW (1) TW533205B (es)
WO (1) WO1997049395A1 (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
KR20060125810A (ko) * 2003-12-19 2006-12-06 노파르티스 아게 （ａ）엔-〔5-［4-（4-메틸-피페라지노-메틸）-벤조일아미도］-2메틸페닐〕-4-（3-피리딜）-2-피리미딘-아민 및（ｂ） 1종 이상의 하이퓨지네이션 억제제의 조합물 및그의 용도
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
CA2594687C (en) * 2005-01-28 2013-10-29 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition
EA014772B1 (ru) * 2005-05-31 2011-02-28 Новартис Аг Лечение заболеваний печени, в патогенезе которых задействовано железо
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
EP1945272B1 (en) 2005-11-01 2013-09-11 Novartis AG Method of scintigraphy
AU2007247112B2 (en) * 2006-05-09 2010-08-26 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
MX2008014837A (es) 2006-05-23 2008-12-01 Novartis Ag Metodo para el tratamiento de hemocromatosis hereditaria.
CL2007002026A1 (es) * 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
CA2659161A1 (en) * 2006-08-04 2008-02-07 Novartis Ag Treatment of endocrine dysfunction using iron chelators
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
BRPI0720793A2 (pt) * 2006-11-29 2014-03-11 Novartis Ag SAIS E FORMAS CRISTALINAS DE ÁCIDO 4-[3,5-BIS(2-HIDRÓXI FENIL)-[1,2,4]tRIAZOL-1-IL]BENZOICO
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
CA2685043A1 (en) * 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
WO2009067557A1 (en) 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
TWI488624B (zh) 2008-09-22 2015-06-21 Nat University Corp Asahikawa Medical College 鐵螯合劑、其製造方法及鐵離子之定量、捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
CA2755273A1 (en) 2009-03-19 2010-09-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
WO2011070560A1 (en) 2009-12-07 2011-06-16 Mapi Pharma Hk Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
EP2929877A1 (en) 2010-07-08 2015-10-14 ratiopharm GmbH Oral dosage form of deferasirox
WO2012025935A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
AP3578A (en) * 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
WO2012069946A1 (en) * 2010-11-24 2012-05-31 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
JP5900968B2 (ja) 2011-01-14 2016-04-06 株式会社ダステック 高分子鉄キレート剤
WO2013053904A1 (en) 2011-10-14 2013-04-18 Photocure Asa Stent
EP2766049A1 (en) 2011-10-14 2014-08-20 Photocure ASA Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
AU2014224252B2 (en) * 2013-03-06 2016-09-22 Biocon Limited Process for the preparation of Deferasirox
PL3124018T3 (pl) * 2013-03-08 2018-05-30 Novartis Ag Doustne formulacje deferazyroksu
CA2911671A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP2946771B1 (en) 2014-05-20 2019-03-20 Sanovel Ilac Sanayi ve Ticaret A.S. Water-dispersible tablet formulation comprising deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
SG11201706756VA (en) 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
KR101695970B1 (ko) 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
AU2016342310B2 (en) 2015-10-23 2020-08-27 Vifor (International) Ag Novel ferroportin inhibitors
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (es) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
DE69716602D1 (de) 2002-11-28
LTPA2007001I1 (lt) 2018-06-25
DE69716602T2 (de) 2003-06-26
LU91291I9 (es) 2018-12-27
LTC0914118I2 (lt) 2018-12-27
US6723742B2 (en) 2004-04-20
CN1223579A (zh) 1999-07-21
NO986024L (no) 1998-12-21
NO2006017I1 (no) 2006-12-18
US6596750B2 (en) 2003-07-22
HUP9903111A2 (hu) 2000-01-28
AU718037B2 (en) 2000-04-06
SI0914118T1 (en) 2003-04-30
SK178598A3 (en) 1999-06-11
KR100616378B1 (ko) 2006-08-28
NO2018014I2 (no) 2018-11-19
NZ333308A (en) 2000-05-26
CZ427298A3 (cs) 1999-03-17
DE122007000020I2 (de) 2010-12-30
PL194758B1 (pl) 2007-07-31
CY2429B1 (en) 2004-11-12
PT914118E (pt) 2003-02-28
NO986024D0 (no) 1998-12-21
CN1146415C (zh) 2004-04-21
JP2000507601A (ja) 2000-06-20
CY2007005I2 (el) 2018-12-12
HUP9903111A3 (en) 2000-06-28
US20030203954A1 (en) 2003-10-30
FR06C0049I1 (es) 2007-03-09
HU226232B1 (en) 2008-07-28
ES2187785T3 (es) 2003-06-16
KR20050098029A (ko) 2005-10-10
LU91291I2 (fr) 2007-01-29
NL300248I2 (nl) 2007-03-01
SK284319B6 (sk) 2005-01-03
DE122007000020I1 (de) 2007-05-24
FR06C0049I2 (fr) 2007-04-27
OA10946A (en) 2003-02-27
MY129541A (en) 2007-04-30
CA2255951A1 (en) 1997-12-31
IL127212A0 (en) 1999-09-22
TR199802693T2 (xx) 1999-05-21
RU2208010C2 (ru) 2003-07-10
AP1127A (en) 2002-12-06
PL330119A1 (en) 1999-04-26
TW533205B (en) 2003-05-21
EP0914118B1 (en) 2002-10-23
BG64248B1 (bg) 2004-07-30
BG103003A (en) 1999-09-30
ATE226435T1 (de) 2002-11-15
DK0914118T3 (da) 2003-02-24
CY2007005I1 (el) 2010-07-28
NL300248I1 (nl) 2007-02-01
WO1997049395A1 (en) 1997-12-31
US20030069273A1 (en) 2003-04-10
AU3262997A (en) 1998-01-14
GEP20084355B (es) 2008-04-29
US6465504B1 (en) 2002-10-15
NO2018014I1 (no) 2018-04-17
JP3541042B2 (ja) 2004-07-07
AR007479A1 (es) 1999-10-27
NO317180B1 (no) 2004-09-06
CA2255951C (en) 2006-10-10
NO2006017I2 (no) 2011-07-04
EP0914118A1 (en) 1999-05-12
BR9709973A (pt) 1999-08-10
AP9801407A0 (en) 1998-12-31
CZ291470B6 (cs) 2003-03-12

Similar Documents

Publication Publication Date Title
HK1020530A1 (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
NZ329176A (en) 2,5-dioxo-imidazolidine derivatives and medicaments
PL329484A1 (en) Triazolyl merkaptides and their apllication as microbicides
EP0788489A4 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE
GB2290538B (en) Metal organic compounds and their use
HUP9600730A1 (en) 1,4-tetrazolinone-derivatives and use thereof as herbicides
GB9422682D0 (en) Herbicidal methods, compositions and compounds
HK1023124A1 (en) Oxime derivatives and their use as fungicides
GB9426290D0 (en) Composition,compound and use
HK1044771A1 (zh) 雜環n-丙酮基苯甲酰胺以及它們作為殺菌劑的使用
SG81238A1 (en) Use of triphenylmethyl-1,2,3-triazoles
GB9422162D0 (en) Composition, compound and use
GB9426293D0 (en) Composition,compound and use
HUP9601395A2 (en) Composition containing amino-triazole and 1,2,4-triazin-5-on derivative and use thereof
PL301984A1 (en) Derivatives of 3-phenyl-5-methylisoxzaole and 4,5-dihydroisoxasole
SI0888356T1 (en) Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
GB9620738D0 (en) Sordarin and derivatives thereof for use as crop antifungal agents
PL303026A1 (en) Novel heterocyclic sulphonamidic compounds and pharmaceutical agent
HU9403034D0 (en) Fungicidal compositions and process for their use
ZA972790B (en) Heterocyclic compounds and their preparation and use.
ZA958962B (en) Heterocyclic compounds and their preparations and use

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170623